If this is your company, CONTACT US to activate Packbase™ software to build your portal.
Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the approved delivery device for Bausch+Lomb’s Levofree Multidose in France. This marks the first approval by the French National Agency for Medicines and Health Products Safety (ANSM) for Aptar Pharma’s Ophthalmic Squeeze Dispenser.
Levofree is a prescription product for the treatment of allergic conjunctivitis. ANSM approved the multidose dispenser and drug combination in May 2018. This approval further expands the regulatory acceptance of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for preservative-free Eye Care formulations.
Addressing the needs of patients and industry
When developing novel Eye Care products, pharmaceutical companies need to deliver improved patient safety, accurate dosing and product integrity. Aptar Pharma’s Ophthalmic Squeeze Dispenser meets these key industry and patient needs.
Meeting regulatory requirements worldwide
Aptar Pharma has been working closely with Bausch+Lomb, one of the world’s leading Eye Care companies, to achieve this first ANSM approval of an Eye Care product in its multidose device.
The ANSM approval culminates a long and robust process. Prior to approval, Bausch and Lomb provided comprehensive, detailed microbiological study results which showed that microorganisms can neither survive nor form colonies in or on the container. In addition, user studies were performed that confirmed the user-friendliness of the multidose device within the patient target group.
The Ophthalmic Squeeze Dispenser is also the first and only FDA-reviewed delivery system for multidose, preservative-free Eye Care products.